Amazfit Announces Ultra Runner Rod Farvard as New Brand Ambassador
23.7.2025 15:00:00 CEST | Business Wire | Press Release
Amazfit, a leading global smart wearables brand owned by Zepp Health (NYSE: ZEPP), announced ultra runner Rod Farvard as the newest athlete ambassador. Farvard’s approach to endurance racing, a combination of strategic training and smart recovery, mirrors Amazfit’s commitment to providing innovative and reliable performance, recovery and sleep tracking technology to everyday and elites athletes alike.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250723541349/en/
Amazfit Announces Ultra Runner Rod Farvard as New Brand Ambassador
Farvard set out as a high school cross country runner before transitioning to triathlons and ultimately landing on ultra racing. He has been motivated throughout his career by a DNF result from high school that has helped propel him to complete some of the world’s most grueling endurance races on the planet, including the Western States 100, UTMB, and the Moab 240. Farvard has also completed the multi-day challenge on the 214-mile-long John Muir Trail where he set a new Fastest Known Time (supported, north to south) of 3 days, 16 hours, and 2 minutes. Whether running through high-altitude terrain or battling the elements for 100+ miles, he relies on precise data to guide his performance, recovery and nutrition. Farvard will integrate the Amazfit T-Rex 3 smartwatch, Helio Strap and Zepp App ecosystem into his training and race routine, highlighting features such as GPS accuracy, heart rate monitoring, VO₂ Max, sleep and recovery tracking, and more.
“Ultra running is all about managing the variables, pacing, nutrition and recovery, while pushing your body to the limit," said Farvard. "With Amazfit, I get reliable tracking capabilities and the necessary tools to optimize race days and recovery. I get real-time feedback that helps me stay in tune with my body no matter how long the race. It’s like having a coach on my wrist that doesn’t miss a beat.”
Farvard joins Italian distance runner Yemaneberhan "Yeman" Crippa and triathlete Morgan Pearson to Amazfit's growing roster of endurance ambassadors. He will work closely with Amazfit on product testing, athlete-led storytelling, and grassroots community events to help bring the brand’s endurance-focused innovations to life. He joins a growing roster of Amazfit ambassadors who represent excellence across running, fitness, and outdoor adventure.
According to Scott Shepley, Head of Global Marketing at Amazfit,“Rod brings an unmatched level of authenticity to our performance-driven community. He’s not just running 100-mile races, he’s relying on data captured from Amazfit products to test the limits, and show what’s possible with the right tools and mindset. His insight as an ultra runner will help us continue to innovate for the running and endurance communities.”
Explore the full range of Amazfit smart wearables and experience innovation that elevates performance, recovery, and precision at www.amazfit.com.
For more information, please visit Amazfit.com and follow us on Facebook, Instagram, Twitter and YouTube.
About Amazfit
Amazfit, a leading global smart wearable brand focused on health and fitness, is part of Zepp Health (NYSE: ZEPP), a health technology company with its principal office based in Gorinchem, the Netherlands. Zepp Health operates as a distributed organization, with team members and offices across the Americas, Europe, Asia, and other global markets.
Offering a wide selection of smartwatches and bands, Amazfit's brand tagline, “Discover Amazing,” encourages individuals to break barriers, exceed expectations, and find joy in every moment. Amazfit is powered by Zepp Health’s proprietary health management platform, which delivers cloud-based, 24/7 actionable insights and guidance to help users achieve their wellness goals.
Known for outstanding craftsmanship, Amazfit smartwatches have won numerous design awards, including the iF Design Award and the Red Dot Design Award. Launched in 2015, Amazfit is embraced by millions of users, with products available in over 90 countries across the Americas, EMEA, and APAC regions. For more information, visit www.amazfit.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250723541349/en/
Contacts
Media Contact:
Mary Woodbury, 914-714-8358, Mary.woodbury@zepp.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom